Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma

AIM: To establish the safety and feasibility of rapidly infusing rituximab over 90 min in patients with primary CNS lymphoma (PCNSL). PATIENTS & METHODS: We retrospectively reviewed all patients with PCNSL who received rapid rituximab infusions (RRI) from January 2016 to January 2017. Primary en...

Descripción completa

Detalles Bibliográficos
Autores principales: Modelevsky, Lisa, Tizon, Richard, Reiss, Samantha N, Smith, Marcel, Garonce, Rachel, Kaley, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200062/
https://www.ncbi.nlm.nih.gov/pubmed/30221993
http://dx.doi.org/10.2217/cns-2018-0001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6200062/
https://www.ncbi.nlm.nih.gov/pubmed/30221993
http://dx.doi.org/10.2217/cns-2018-0001

Ejemplares similares